Lexaria Bioscience Corp. (CSE:LXX; OTCBB:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i.e. fat soluble) and difficult for the human gastrointestinal system to efficiently and effectively absorb. DehydraTECH™ greatly improves the body’s ability to absorb these substances so their benefits can be received more quickly and pleasantly.
Lexaria has multiple patents issued or pending in over 40 countries around the world.
Lexaria Bioscience Corp. evolved into its current form in 2014 upon controlling acquisition of the former company where Lexaria’s DehydraTECH™ technology originated. Since then, Lexaria has quickly emerged as a global leader in enhancing the flavor, bouquet and gastro-intestinal delivery of edible cannabinoid consumer products while also working to expand the applicability of its technology, within and beyond the cannabinoid sector, through its out-licensing business model for cannabinoids and other bioactive molecules named in its patent portfolio (NSAIDs, nicotine, vitamins and more). Lexaria produces industry-leading research to support its novel delivery method. None of this can happen without the talented and dedicated people who have supported Lexaria’s development and growth.
Lexaria has always maximized its resources by attracting top management and advisors and also leveraging the strongest expert consultant relationships. Supporters have included industry leaders, research scientists, clinicians, analytical chemists, intellectual property experts, study volunteers, partnering company collaborators and, of course, the original inventors of the earliest iterations of Lexaria’s DehydraTECH™ technology.